Personal information

No personal information available

Activities

Collapse all

Employment (1)

Kaohsiung Medical University College of Medicine: Kaohsiung, TW

Professor (Department of Internal Medicine)
Employment
Source: Self-asserted source
Li-Tzong Chen

Works (39)

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer

ESMO Open
2024-08 | Journal article
DOI: 10.1016/j.esmoop.2024.103647
Contributors: L.-T. Chen; A. Vogel; C. Hsu; M.-H. Chen; W. Fang; E.A. Pangarsa; A. Sharma; M. Ikeda; J.O. Park; C.K. Tan et al.
Source: check_circle
Crossref

A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

Cancer Research Communications
2024-04-30 | Journal article
DOI: 10.1158/2767-9764.CRC-24-0137
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

Data from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

2024-04-30 | Preprint
DOI: 10.1158/2767-9764.c.7207754
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

Data from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

2024-04-30 | Preprint
DOI: 10.1158/2767-9764.c.7207754.v1
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

FIGURE 1 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

2024-04-30 | Preprint
DOI: 10.1158/2767-9764.25723508
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

FIGURE 1 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

2024-04-30 | Preprint
DOI: 10.1158/2767-9764.25723508.v1
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

FIGURE 2 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

2024-04-30 | Preprint
DOI: 10.1158/2767-9764.25723505
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

FIGURE 2 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

2024-04-30 | Preprint
DOI: 10.1158/2767-9764.25723505.v1
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

FIGURE 3 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

2024-04-30 | Preprint
DOI: 10.1158/2767-9764.25723502
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

FIGURE 3 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

2024-04-30 | Preprint
DOI: 10.1158/2767-9764.25723502.v1
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

Supplementary Figure 1 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

2024-04-30 | Preprint
DOI: 10.1158/2767-9764.25723499.v1
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

Supplementary Figure 1 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

2024-04-30 | Preprint
DOI: 10.1158/2767-9764.25723499
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

Supplementary Figure 2 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

2024-04-30 | Preprint
DOI: 10.1158/2767-9764.25723496
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

Supplementary Figure 2 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

2024-04-30 | Preprint
DOI: 10.1158/2767-9764.25723496.v1
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

Supplementary Figure 3 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

2024-04-30 | Preprint
DOI: 10.1158/2767-9764.25723493
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

Supplementary Figure 3 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

2024-04-30 | Preprint
DOI: 10.1158/2767-9764.25723493.v1
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

Supplementary Figure 4 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

2024-04-30 | Preprint
DOI: 10.1158/2767-9764.25723490
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

Supplementary Figure 4 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

2024-04-30 | Preprint
DOI: 10.1158/2767-9764.25723490.v1
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

Supplementary Figure 5 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

2024-04-30 | Preprint
DOI: 10.1158/2767-9764.25723487
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

Supplementary Figure 5 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

2024-04-30 | Preprint
DOI: 10.1158/2767-9764.25723487.v1
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

Supplementary Methods from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

2024-04-30 | Preprint
DOI: 10.1158/2767-9764.25723484
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

Supplementary Methods from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

2024-04-30 | Preprint
DOI: 10.1158/2767-9764.25723484.v1
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

Supplementary Table 1 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

2024-04-30 | Preprint
DOI: 10.1158/2767-9764.25723481
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

Supplementary Table 1 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

2024-04-30 | Preprint
DOI: 10.1158/2767-9764.25723481.v1
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

Supplementary Table 2 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

2024-04-30 | Preprint
DOI: 10.1158/2767-9764.25723478.v1
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

Supplementary Table 2 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

2024-04-30 | Preprint
DOI: 10.1158/2767-9764.25723478
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

Supplementary Table 3 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

2024-04-30 | Preprint
DOI: 10.1158/2767-9764.25723475
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

Supplementary Table 3 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

2024-04-30 | Preprint
DOI: 10.1158/2767-9764.25723475.v1
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

Supplementary Table 4 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

2024-04-30 | Preprint
DOI: 10.1158/2767-9764.25723472
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

Supplementary Table 4 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

2024-04-30 | Preprint
DOI: 10.1158/2767-9764.25723472.v1
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

TABLE 1 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

2024-04-30 | Preprint
DOI: 10.1158/2767-9764.25723469
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

TABLE 1 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

2024-04-30 | Preprint
DOI: 10.1158/2767-9764.25723469.v1
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

TABLE 2 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

2024-04-30 | Preprint
DOI: 10.1158/2767-9764.25723466
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

TABLE 2 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

2024-04-30 | Preprint
DOI: 10.1158/2767-9764.25723466.v1
Contributors: Benjamin Garmezy; Mitesh J. Borad; Rastilav Bahleda; Cesar A. Perez; Li-Tzong Chen; Shumei Kato; Do-Youn Oh; Paul Severson; Betty Y. Tam; Cheng S. Quah et al.
Source: check_circle
Crossref

The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan

ESMO Open
2023-02 | Journal article
DOI: 10.1016/j.esmoop.2022.100746
Contributors: Y.-Y. Su; N.-J. Chiang; J.S. Chang; Y.-W. Wang; B.-N. Shen; Y.-J. Li; D.-Y. Hwang; Y.-S. Shan; L.-T. Chen
Source: check_circle
Crossref

Transcriptional suppression of Dicer by HOXB‐AS3/EZH2 complex dictates sorafenib resistance and cancer stemness

Cancer Science
2022-05 | Journal article
DOI: 10.1111/cas.15319
Contributors: Chi‐Feng Tseng; Li‐Tzong Chen; Horng‐Dar Wang; Yi‐Hong Liu; Shine‐Gwo Shiah
Source: check_circle
Crossref

Comparing survival and subsequent treatment of first-line tyrosine kinase inhibitors in patients of advanced lung adenocarcinoma with epidermal growth factor receptor mutation

Journal of the Formosan Medical Association
2022-01 | Journal article
DOI: 10.1016/j.jfma.2021.02.012
Contributors: Ming-Yi Huang; Kun-Pin Hsieh; Ru-Yu Huang; Jen-Yu Hung; Li-Tzong Chen; Ming-Ju Tsai; Yi-Hsin Yang
Source: check_circle
Crossref

c‐Myc promotes lymphatic metastasis of pancreatic neuroendocrine tumor through VEGFC upregulation

Cancer Science
2021-01 | Journal article
DOI: 10.1111/cas.14717
Contributors: Tsung‐Ming Chang; Pei‐Yi Chu; Wen‐Chun Hung; Yan‐Shen Shan; Hui‐You Lin; Kuo‐Wei Huang; Jeffrey S. Chang; Li‐Tzong Chen; Hui‐Jen Tsai
Source: check_circle
Crossref

Multicentre, phase II study of gemcitabine and S‐1 in patients with advanced biliary tract cancer: TG1308 study

Liver International
2020-10 | Journal article
DOI: 10.1111/liv.14538
Contributors: Nai‐Jung Chiang; Ming‐Huang Chen; Shih‐Hung Yang; Chiun Hsu; Chia‐Jui Yen; Hsiao‐Hui Tsou; Yung‐Yeh Su; Jen‐Shi Chen; Yan‐Shen Shan; Li‐Tzong Chen
Source: check_circle
Crossref

Peer review (8 reviews for 5 publications/grants)

Review activity for BMJ (1)
Review activity for Hepatology international. (3)
Review activity for Journal of biomedical science (2)
Review activity for Journal of experimental & clinical cancer research. (1)
Review activity for Nature reviews. (1)
How many people are using ORCID?